Screening and diagnosis of prediabetes: where are we headed?

被引:19
作者
Alberti, K. G. M. M. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Endocrinol & Metab Med, London W2 1NY, England
关键词
fasting plasma glucose testing; impaired glucose tolerance; oral glucose tolerance testing; prediabetes; risk assessment; type; 2; diabetes;
D O I
10.1111/j.1463-1326.2007.00764.x
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
It is currently estimated that more than 300 million people have impaired glucose tolerance (IGT), putting them at increased risk for type 2 diabetes mellitus (T2DM) and its adverse consequences. In addition, many others are at risk on the basis of a family history of T2DM, obesity, dyslipidaemia and hypertension. Screening for risk should include both blood glucose testing in high-risk populations and prescreening (e.g. by questionnaire, waist circumference measurement) to identify high-risk individuals in overall low-risk populations; these individuals should then undergo glucose testing. Fasting plasma glucose measurement cannot diagnose IGT; the preferred definite test for diagnosis is oral glucose tolerance testing.
引用
收藏
页码:12 / 16
页数:5
相关论文
共 26 条
[1]
The metabolic syndrome:: A concept hard to define [J].
Aguilar-Salinas, CA ;
Rojas, R ;
Gómez-Pérez, FJ ;
Mehta, R ;
Franco, A ;
Olaiz, G ;
Rull, JA .
ARCHIVES OF MEDICAL RESEARCH, 2005, 36 (03) :223-231
[2]
Type 2 diabetes in the young: The evolving epidemic - The International Diabetes Federation Consensus Workshop [J].
Alberti, G ;
Zimmet, P ;
Shaw, J ;
Bloomgarden, Z ;
Kaufman, F ;
Silink, M .
DIABETES CARE, 2004, 27 (07) :1798-1811
[3]
International Diabetes Federation: a consensus on Type 2 diabetes prevention [J].
Alberti, K. G. M. M. ;
Zimmet, P. ;
Shaw, J. .
DIABETIC MEDICINE, 2007, 24 (05) :451-463
[4]
Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
DIABETIC MEDICINE, 2006, 23 (05) :469-480
[5]
Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria [J].
Borch-Johnsen, K ;
Neil, A ;
Balkau, B ;
Larsen, S ;
Nissinen, A ;
Pekkanen, J ;
Tuomilehto, J ;
Jousilahti, P ;
Lindstrom, J ;
Pyörälä, M ;
Pyörälä, K ;
Eschwege, E ;
Gallus, G ;
Garancini, MP ;
Bouter, LM ;
Dekker, JM ;
Heine, RJ ;
Nijpels, HG ;
Stehouwer, CDA ;
Feskens, EJM ;
Kromhout, D ;
Peltonen, M ;
Pajak, A ;
Eriksson, J ;
Qiao, Q .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) :397-405
[6]
Chiasson J L, 2005, Minerva Endocrinol, V30, P179
[7]
Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[8]
Gavin JR, 1997, DIABETES CARE, V20, P1183
[9]
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial [J].
Gerstein, H. C. ;
Yusuf, S. ;
Holman, R. R. ;
Bosch, J. ;
Anand, S. ;
Avezum, A. ;
Budaj, A. ;
Chiasson, J. ;
Conget, I. ;
Dagenais, G. ;
Davis, M. ;
Diaz, R. ;
Dinccag, N. ;
Enjalbert, M. ;
Escalante, A. ;
Fodor, G. ;
Hanefeld, M. ;
Hedner, T. ;
Jolly, K. ;
Keltai, M. ;
Laakso, M. ;
Lanas, F. ;
Lonn, E. ;
McQueen, M. ;
Mohan, V. ;
Phillips, A. ;
Piegas, L. ;
Pirags, V. ;
Probstfield, J. ;
Shaw, J. ;
Schmid, I. ;
Teo, K. ;
Zimmet, P. ;
Zinman, B. ;
Gerstein, H. C. ;
Yusuf, S. ;
Bosch, J. ;
Pogue, J. ;
Sheridan, P. ;
Dinccag, N. ;
Hanefeld, M. ;
Hoogwerf, B. ;
Laakso, M. ;
Mohan, V. ;
Shaw, J. ;
Zinman, B. ;
Holman, R. R. ;
Diaz, R. ;
Ahuad Guerrero, R. ;
Albisu, J. .
LANCET, 2006, 368 (9541) :1096-1105
[10]
Grundy Scott M, 2005, Clin Cornerstone, V7, P36, DOI 10.1016/S1098-3597(05)80066-3